The mutational spectrum of atypical meningiomas is mainly characterized by NF2 mutations [16] that co-occur with genomic instability or recurrent SMARCB1 mutations in primary atypical meningiomas, and with TERT promoter mutations in secondary (i.e., arisen from the progression of benign tumors) ones [17]. This evidence concerns the gene NF2 and meningioma.